Hematopathologist
3 weeks ago
Genomic Testing Cooperative, LCA (GTC) is recruiting for a full-time Molecular hematopathologist to be a part of the innovation team at GTC and to support the growth of the company.
GTC is specialized in Next Generation Sequencing (NGS) offering extensive molecular profiling of hematologic neoplasms and solid tumors.
GTC uses state-of-the-art DNA and RNA sequencing with proprietary data analysis software and algorithms based on AI and machine learning.
This position represents an exciting opportunity for motivated molecular Hematopathologists or hematopathologists with backgrounds in molecular and bioinformatics.
Join a unique company and be a part of a highly innovative team that is leading in precision oncology. This position offers a tremendous opportunity to learn and gain experience in next-generation sequencing, bioinformatics, deep learning, software engineering, and the science of developing new clinically relevant tests. Join our team and enjoy a healthy work-life in Southern California.
The position is full-time with competitive compensation and comprehensive benefits. Board certification in Hematopathology is required.
Equal Opportunity Employer including disability/veteran.
Company Description"Genomic Testing Cooperative (GTC), is a Limited Cooperative Association, that offers multiple laboratory-developed genomic profiling tests for hematologic and solid tumors using next-generation sequencing (NGS) technology. The co-op provides a first of its kind platform for cooperation between commercial, hospital-based, and academic laboratories. “In the era of precision medicine, we at the Genomic Testing Cooperative, believe that every patient with cancer has the right to affordable molecular profiling of their cancer so clear treatment options can be explored.” At this time, 8 different cancer genomic profiling tests are available."Company Description"Genomic Testing Cooperative (GTC), is a Limited Cooperative Association, that offers multiple laboratory-developed genomic profiling tests for hematologic and solid tumors using next-generation sequencing (NGS) technology. The co-op provides a first of its kind platform for cooperation between commercial, hospital-based, and academic laboratories. “In the era of precision medicine, we at the Genomic Testing Cooperative, believe that every patient with cancer has the right to affordable molecular profiling of their cancer so clear treatment options can be explored.” At this time, 8 different cancer genomic profiling tests are available."